Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.

Keck ZY, Pierce BG, Lau P, Lu J, Wang Y, Underwood A, Bull RA, Prentoe J, Velázquez-Moctezuma R, Walker MR, Luciani F, Guest JD, Fauvelle C, Baumert TF, Bukh J, Lloyd AR, Foung SKH.

PLoS Pathog. 2019 May 17;15(5):e1007772. doi: 10.1371/journal.ppat.1007772. eCollection 2019 May.

2.

Interferon-Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection.

Wrensch F, Ligat G, Heydmann L, Schuster C, Zeisel MB, Pessaux P, Habersetzer F, King BJ, Tarr AW, Ball JK, Winkler M, Pöhlmann S, Keck ZY, Foung SKH, Baumert TF.

Hepatology. 2019 May 7. doi: 10.1002/hep.30699. [Epub ahead of print]

PMID:
31062385
3.

Learning from a clinical cohort for HCV vaccine development.

Wrensch F, Keck ZY, Foung SKH, Baumert TF.

J Hepatol. 2019 Jul;71(1):9-11. doi: 10.1016/j.jhep.2019.03.030. Epub 2019 Apr 13. No abstract available.

PMID:
30992137
4.

Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells.

Urbanowicz RA, Wang R, Schiel JE, Keck ZY, Kerzic MC, Lau P, Rangarajan S, Garagusi KJ, Tan L, Guest JD, Ball JK, Pierce BG, Mariuzza RA, Foung SKH, Fuerst TR.

J Virol. 2019 Mar 21;93(7). pii: e01403-18. doi: 10.1128/JVI.01403-18. Print 2019 Apr 1.

5.

In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.

Mailly L, Wrensch F, Heydmann L, Fauvelle C, Brignon N, Zeisel MB, Pessaux P, Keck ZY, Schuster C, Fuerst TR, Foung SKH, Baumert TF.

Antiviral Res. 2019 Feb;162:136-141. doi: 10.1016/j.antiviral.2018.12.018. Epub 2018 Dec 30.

PMID:
30599173
6.

Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).

Bailey JR, Urbanowicz RA, Ball JK, Law M, Foung SKH.

Methods Mol Biol. 2019;1911:441-450. doi: 10.1007/978-1-4939-8976-8_30.

7.

Isolation of HCV Neutralizing Antibodies by Yeast Display.

Keck ZY, Wang Y, Lau P, Foung SKH.

Methods Mol Biol. 2019;1911:395-419. doi: 10.1007/978-1-4939-8976-8_27.

8.

Editorial: Current Progress and Challenges in the Development of a B Cell Based Hepatitis C Virus Vaccine.

Foung SKH, Baumert TF.

Front Immunol. 2018 Nov 9;9:2577. doi: 10.3389/fimmu.2018.02577. eCollection 2018. No abstract available.

9.

Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design.

Wrensch F, Crouchet E, Ligat G, Zeisel MB, Keck ZY, Foung SKH, Schuster C, Baumert TF.

Front Immunol. 2018 Jun 21;9:1436. doi: 10.3389/fimmu.2018.01436. eCollection 2018. Review.

10.

Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine.

Keck ML, Wrensch F, Pierce BG, Baumert TF, Foung SKH.

Front Immunol. 2018 May 31;9:1194. doi: 10.3389/fimmu.2018.01194. eCollection 2018. Review.

11.

Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine.

Christiansen D, Earnest-Silveira L, Chua B, Meuleman P, Boo I, Grubor-Bauk B, Jackson DC, Keck ZY, Foung SKH, Drummer HE, Gowans EJ, Torresi J.

Sci Rep. 2018 Apr 24;8(1):6483. doi: 10.1038/s41598-018-24762-9.

12.

Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus.

Fuerst TR, Pierce BG, Keck ZY, Foung SKH.

Front Microbiol. 2018 Jan 15;8:2692. doi: 10.3389/fmicb.2017.02692. eCollection 2017. Review.

13.

Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.

Mesalam AA, Desombere I, Farhoudi A, Van Houtte F, Verhoye L, Ball J, Dubuisson J, Foung SKH, Patel AH, Persson MAA, Leroux-Roels G, Meuleman P.

Virology. 2018 Jan 15;514:30-41. doi: 10.1016/j.virol.2017.10.019. Epub 2017 Nov 10.

14.

A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.

Desombere I, Mesalam AA, Urbanowicz RA, Van Houtte F, Verhoye L, Keck ZY, Farhoudi A, Vercauteren K, Weening KE, Baumert TF, Patel AH, Foung SKH, Ball J, Leroux-Roels G, Meuleman P.

Antiviral Res. 2017 Dec;148:53-64. doi: 10.1016/j.antiviral.2017.10.015. Epub 2017 Oct 23.

15.

Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.

Vasiliauskaite I, Owsianka A, England P, Khan AG, Cole S, Bankwitz D, Foung SKH, Pietschmann T, Marcotrigiano J, Rey FA, Patel AH, Krey T.

MBio. 2017 May 16;8(3). pii: e00382-17. doi: 10.1128/mBio.00382-17.

16.

Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection.

Swann RE, Mandalou P, Robinson MW, Ow MM, Foung SK, McLauchlan J, Patel AH, Cramp ME.

J Viral Hepat. 2016 Nov;23(11):873-880. doi: 10.1111/jvh.12568. Epub 2016 Jul 13.

17.

Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.

Logan M, Law J, Wong JAJ, Hockman D, Landi A, Chen C, Crawford K, Kundu J, Baldwin L, Johnson J, Dahiya A, LaChance G, Marcotrigiano J, Law M, Foung S, Tyrrell L, Houghton M.

J Virol. 2016 Dec 16;91(1). pii: e01552-16. doi: 10.1128/JVI.01552-16. Print 2017 Jan 1.

18.

Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.

Pierce BG, Keck ZY, Lau P, Fauvelle C, Gowthaman R, Baumert TF, Fuerst TR, Mariuzza RA, Foung SKH.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):E6946-E6954. doi: 10.1073/pnas.1614942113. Epub 2016 Oct 26.

19.

Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice.

Keck ZY, Wang Y, Lau P, Lund G, Rangarajan S, Fauvelle C, Liao GC, Holtsberg FW, Warfield KL, Aman MJ, Pierce BG, Fuerst TR, Bailey JR, Baumert TF, Mariuzza RA, Kneteman NM, Foung SK.

Hepatology. 2016 Dec;64(6):1922-1933. doi: 10.1002/hep.28850. Epub 2016 Oct 28.

20.

Viral evasion and challenges of hepatitis C virus vaccine development.

Pierce BG, Keck ZY, Foung SK.

Curr Opin Virol. 2016 Oct;20:55-63. doi: 10.1016/j.coviro.2016.09.004. Epub 2016 Sep 19. Review.

21.

Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.

Prentoe J, Velázquez-Moctezuma R, Foung SK, Law M, Bukh J.

Hepatology. 2016 Dec;64(6):1881-1892. doi: 10.1002/hep.28705. Epub 2016 Aug 9.

22.

Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.

Fauvelle C, Colpitts CC, Keck ZY, Pierce BG, Foung SK, Baumert TF.

Expert Rev Vaccines. 2016 Dec;15(12):1535-1544. Epub 2016 Jun 13. Review.

23.

Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.

Howell KA, Qiu X, Brannan JM, Bryan C, Davidson E, Holtsberg FW, Wec AZ, Shulenin S, Biggins JE, Douglas R, Enterlein SG, Turner HL, Pallesen J, Murin CD, He S, Kroeker A, Vu H, Herbert AS, Fusco ML, Nyakatura EK, Lai JR, Keck ZY, Foung SKH, Saphire EO, Zeitlin L, Ward AB, Chandran K, Doranz BJ, Kobinger GP, Dye JM, Aman MJ.

Cell Rep. 2016 May 17;15(7):1514-1526. doi: 10.1016/j.celrep.2016.04.026. Epub 2016 May 5.

24.

Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.

Keck ZY, Girard-Blanc C, Wang W, Lau P, Zuiani A, Rey FA, Krey T, Diamond MS, Foung SK.

J Virol. 2016 Jan 6;90(6):3112-22. doi: 10.1128/JVI.02458-15.

25.

Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.

Keck ZY, Enterlein SG, Howell KA, Vu H, Shulenin S, Warfield KL, Froude JW, Araghi N, Douglas R, Biggins J, Lear-Rooney CM, Wirchnianski AS, Lau P, Wang Y, Herbert AS, Dye JM, Glass PJ, Holtsberg FW, Foung SK, Aman MJ.

J Virol. 2015 Oct 14;90(1):279-91. doi: 10.1128/JVI.02172-15. Print 2016 Jan 1.

26.

Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies.

Fauvelle C, Felmlee DJ, Crouchet E, Lee J, Heydmann L, Lefèvre M, Magri A, Hiet MS, Fofana I, Habersetzer F, Foung SK, Milne R, Patel AH, Vercauteren K, Meuleman P, Zeisel MB, Bartenschlager R, Schuster C, Baumert TF.

Gastroenterology. 2016 Jan;150(1):206-217.e4. doi: 10.1053/j.gastro.2015.09.014. Epub 2015 Sep 25.

PMID:
26404951
27.

Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody.

Li Y, Pierce BG, Wang Q, Keck ZY, Fuerst TR, Foung SK, Mariuzza RA.

J Biol Chem. 2015 Apr 17;290(16):10117-25. doi: 10.1074/jbc.M115.643528. Epub 2015 Mar 3.

28.

An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection.

Zanin M, Keck ZY, Rainey GJ, Lam CY, Boon AC, Rubrum A, Darnell D, Wong SS, Griffin Y, Xia J, Webster RG, Webby R, Johnson S, Foung S.

J Virol. 2015 Apr;89(8):4549-61. doi: 10.1128/JVI.00078-15. Epub 2015 Feb 11.

29.

Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.

Bailey JR, Wasilewski LN, Snider AE, El-Diwany R, Osburn WO, Keck Z, Foung SK, Ray SC.

J Clin Invest. 2015 Jan;125(1):437-47. doi: 10.1172/JCI78794. Epub 2014 Dec 15.

30.

Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.

Meola A, Tarr AW, England P, Meredith LW, McClure CP, Foung SK, McKeating JA, Ball JK, Rey FA, Krey T.

J Virol. 2015 Feb;89(4):2170-81. doi: 10.1128/JVI.02190-14. Epub 2014 Dec 3.

31.

Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423.

Keck ZY, Angus AG, Wang W, Lau P, Wang Y, Gatherer D, Patel AH, Foung SK.

PLoS Pathog. 2014 Aug 14;10(8):e1004297. doi: 10.1371/journal.ppat.1004297. eCollection 2014 Aug.

32.

Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.

Carlsen TH, Pedersen J, Prentoe JC, Giang E, Keck ZY, Mikkelsen LS, Law M, Foung SK, Bukh J.

Hepatology. 2014 Nov;60(5):1551-62. doi: 10.1002/hep.27298. Epub 2014 Oct 2.

33.

Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies.

Pedersen J, Carlsen TH, Prentoe J, Ramirez S, Jensen TB, Forns X, Alter H, Foung SK, Law M, Gottwein J, Weis N, Bukh J.

Hepatology. 2013 Nov;58(5):1587-97. doi: 10.1002/hep.26524. Epub 2013 Aug 7.

34.

Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape.

Krey T, Meola A, Keck ZY, Damier-Piolle L, Foung SK, Rey FA.

PLoS Pathog. 2013;9(5):e1003364. doi: 10.1371/journal.ppat.1003364. Epub 2013 May 16.

35.

Contrasting roles of mitogen-activated protein kinases in cellular entry and replication of hepatitis C virus: MKNK1 facilitates cell entry.

Kim S, Ishida H, Yamane D, Yi M, Swinney DC, Foung S, Lemon SM.

J Virol. 2013 Apr;87(8):4214-24. doi: 10.1128/JVI.00954-12. Epub 2013 Jan 30.

36.

Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry.

Carlsen TH, Scheel TK, Ramirez S, Foung SK, Bukh J.

J Virol. 2013 Feb;87(3):1385-99. doi: 10.1128/JVI.00684-12. Epub 2012 Nov 14.

37.

Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein.

Keck Z, Wang W, Wang Y, Lau P, Carlsen TH, Prentoe J, Xia J, Patel AH, Bukh J, Foung SK.

J Virol. 2013 Jan;87(1):37-51. doi: 10.1128/JVI.01941-12. Epub 2012 Oct 24.

38.

Transient activation of the PI3K-AKT pathway by hepatitis C virus to enhance viral entry.

Liu Z, Tian Y, Machida K, Lai MM, Luo G, Foung SK, Ou JH.

J Biol Chem. 2012 Dec 7;287(50):41922-30. doi: 10.1074/jbc.M112.414789. Epub 2012 Oct 24.

39.

Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody.

Potter JA, Owsianka AM, Jeffery N, Matthews DJ, Keck ZY, Lau P, Foung SK, Taylor GL, Patel AH.

J Virol. 2012 Dec;86(23):12923-32. doi: 10.1128/JVI.02052-12. Epub 2012 Sep 19.

40.

Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.

Keck ZY, Xia J, Wang Y, Wang W, Krey T, Prentoe J, Carlsen T, Li AY, Patel AH, Lemon SM, Bukh J, Rey FA, Foung SK.

PLoS Pathog. 2012;8(4):e1002653. doi: 10.1371/journal.ppat.1002653. Epub 2012 Apr 12.

41.

Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.

Fofana I, Fafi-Kremer S, Carolla P, Fauvelle C, Zahid MN, Turek M, Heydmann L, Cury K, Hayer J, Combet C, Cosset FL, Pietschmann T, Hiet MS, Bartenschlager R, Habersetzer F, Doffoël M, Keck ZY, Foung SKH, Zeisel MB, Stoll-Keller F, Baumert TF.

Gastroenterology. 2012 Jul;143(1):223-233.e9. doi: 10.1053/j.gastro.2012.04.006. Epub 2012 Apr 10.

42.

Neutralizing antibody response to hepatitis C virus.

Wang Y, Keck ZY, Foung SK.

Viruses. 2011 Nov;3(11):2127-45. doi: 10.3390/v3112127. Epub 2011 Nov 2. Review.

43.

Hepatitis C virus e2 protein ectodomain is essential for assembly of infectious virions.

Bianchi A, Crotta S, Brazzoli M, Foung SK, Merola M.

Int J Hepatol. 2011;2011:968161. doi: 10.4061/2011/968161. Epub 2010 Oct 12.

44.

Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.

Wang Y, Keck ZY, Saha A, Xia J, Conrad F, Lou J, Eckart M, Marks JD, Foung SK.

J Biol Chem. 2011 Dec 23;286(51):44218-33. doi: 10.1074/jbc.M111.290783. Epub 2011 Oct 14.

45.

The hepatitis C virus E1 glycoprotein undergoes productive folding but accelerated degradation when expressed as an individual subunit in CHO cells.

Botti V, Bianchi A, Foung SK, Merola M.

PLoS One. 2011;6(8):e23838. doi: 10.1371/journal.pone.0023838. Epub 2011 Aug 17.

46.

Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.

Keck ZY, Saha A, Xia J, Wang Y, Lau P, Krey T, Rey FA, Foung SK.

J Virol. 2011 Oct;85(20):10451-63. doi: 10.1128/JVI.05259-11. Epub 2011 Aug 3.

47.

Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships.

Rychlowska M, Owsianka AM, Foung SK, Dubuisson J, Bienkowska-Szewczyk K, Patel AH.

J Gen Virol. 2011 Oct;92(Pt 10):2249-61. doi: 10.1099/vir.0.034314-0. Epub 2011 Jun 22.

48.

The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae.

Stapleton JT, Foung S, Muerhoff AS, Bukh J, Simmonds P.

J Gen Virol. 2011 Feb;92(Pt 2):233-46. doi: 10.1099/vir.0.027490-0. Epub 2010 Nov 17. Review.

49.

Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.

Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, Zeisel MB, Baumert TF, Keck ZY, Foung SK, Pécheur EI, Pietschmann T.

J Virol. 2010 Jun;84(11):5751-63. doi: 10.1128/JVI.02200-09. Epub 2010 Mar 31.

50.

Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies.

Dhillon S, Witteveldt J, Gatherer D, Owsianka AM, Zeisel MB, Zahid MN, Rychłowska M, Foung SK, Baumert TF, Angus AG, Patel AH.

J Virol. 2010 Jun;84(11):5494-507. doi: 10.1128/JVI.02153-09. Epub 2010 Mar 17.

Supplemental Content

Support Center